公开(公告)号：US20220142982A1

公开(公告)日：2022-05-12

申请号：US17564538

申请日：2021-12-29

申请人： MITSUBISHI TANABE PHARMA CORPORATION

发明人： Hidetoshi SHIMIZU ,  Yoshinobu NAKAMARU ,  Yukiko NISHIMURA

IPC分类号： A61K31/4152 ,  A61P25/28 ,  A61K9/00

摘要： A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.

公开(公告)号：US20220079986A1

公开(公告)日：2022-03-17

申请号：US17424985

申请日：2020-01-23

申请人： The General Hospital Corporation

发明人： Mark C. POZNANSKY ,  Ruxandra F. SIRBULESCU

IPC分类号： A61K35/17 ,  A61K31/4152 ,  A61K31/428 ,  A61K45/06 ,  A61P25/28

摘要： The invention, in general, features a method of treating a neurodegenerative disease (such as amyotrophic lateral sclerosis) or a traumatic brain injury in a subject (e.g., a human) in need thereof, the method comprising administering to the subject a therapeutically effective amount of isolated B cells (such as autologous or allogeneic or xenogeneic B cells).

公开(公告)号：US11273149B2

公开(公告)日：2022-03-15

申请号：US16937168

申请日：2020-07-23

申请人： Dennis Keefe ,  Guozhu Zheng

发明人： Dennis Keefe ,  Guozhu Zheng ,  Vania Broccoli

IPC分类号： A61K31/4245 ,  A61P25/28 ,  A61K31/135 ,  A61K31/197 ,  A61K31/4152 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/5513 ,  A61K38/30

摘要： The present disclosure provides novel methods for treating or preventing amyotrophic lateral sclerosis (ALS), methods for delaying the onset of neurological symptoms associated with ALS, increasing survival in subjects afflicted with ALS, and attenuating the decline of muscle strength associated with ALS in a subject in need thereof. The present disclosure also provides methods for treating or preventing α-synucleinopathy or TDP-43 proteinopathy. The methods comprise administering to the subject an effective amount of a mitochondria-targeting peptidomimetic compound, such as (R)-2-amino-N—((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof.

公开(公告)号：US11213511B2

公开(公告)日：2022-01-04

申请号：US17205809

申请日：2021-03-18

申请人： Syntekabio, Inc.

发明人： Jong Sun Jung ,  Jong Hui Hong ,  Dong Myung Kim ,  Bong Hwan Park ,  Young Bae Ryu ,  Hyung Jun Kwon ,  In Chul Lee ,  Ji Young Park

IPC分类号： A61K31/404 ,  A61K31/4152 ,  A61K9/00 ,  A61P31/14

摘要： Disclosed is a pharmaceutical composition for preventing or treating severe acute respiratory syndrome coronavirus 2 infection disease, the composition comprising a compound represented by a Chemical Formula 1, or a pharmaceutically acceptable salt thereof, as an active ingredient.

公开(公告)号：US20210361619A1

公开(公告)日：2021-11-25

申请号：US17205809

申请日：2021-03-18

申请人： Syntekabio, Inc.

发明人： Jong Sun Jung ,  Jong Hui Hong ,  Dong Myung Kim ,  Bong Hwan Park ,  Young Bae Ryu ,  Hyung Jun Kwon ,  In Chul Lee ,  Ji Young Park

IPC分类号： A61K31/404 ,  A61K31/4152 ,  A61P31/14 ,  A61K9/00

摘要： Disclosed is a pharmaceutical composition for preventing or treating severe acute respiratory syndrome coronavirus 2 infection disease, the composition comprising a compound represented by a Chemical Formula 1, or a pharmaceutically acceptable salt thereof, as an active ingredient.

公开(公告)号：US11160790B2

公开(公告)日：2021-11-02

申请号：US16714867

申请日：2019-12-16

申请人： NATIONAL TAIWAN UNIVERSITY

发明人： Ying-Lien Chen ,  Hao-Tai Ko ,  Li-Hang Hsu ,  Sheng-Yung Yang

IPC分类号： A61K31/4152 ,  A61P31/10 ,  A61K31/436

摘要： Provided is a method of inhibiting the growth of a fungus using eltrombopag, wherein the fungus is selected from the group consisting of Cryptococcus, Candida glabrata, and Trichophyton rubrum. Also provided are a combination agent that includes eltrombopag and a macrolide calcineurin inhibitor and a method of using the combination agent for inhibiting the growth of Cryptococcus. Also provided is a method of inhibiting virulence factor formation in Cryptococcus using eltrombopag.

公开(公告)号：US20210308104A1

公开(公告)日：2021-10-07

申请号：US17263856

申请日：2019-07-26

申请人： SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI

发明人： ALI TURKYILMAZ ,  EDIZ YILDIRIM ,  GULCIN TOK

IPC分类号： A61K31/4152 ,  A61K9/48

摘要： The present invention relates to a pharmaceutical capsule composition comprising eltrombopag olamine or a pharmaceutically acceptable salt thereof for use in the treatment of thrombocytopenia. Furthermore, the present invention relates to an improved, simple, rapid, cost-effective, time-saving and industrially available method of preparing the capsule composition comprising eltrombopag olamine.

公开(公告)号：US20210284629A1

公开(公告)日：2021-09-16

申请号：US17053929

申请日：2019-05-09

申请人： Design Therapeutics, Inc.

发明人： Aseem ANSARI ,  Pratik SHAH

IPC分类号： C07D403/14 ,  A61K31/428 ,  A61K31/4152

摘要： The present disclosure relates to compounds and methods for modulating the expression ofc9orf72 (brain expressed, associated with NEDD4) and treating diseases and conditions in which c9orf72 plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence GGGGCC; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence GGGGCC; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

公开(公告)号：US11058647B1

公开(公告)日：2021-07-13

申请号：US16946875

申请日：2020-07-09

申请人： Applied Biology, Inc.

发明人： Ofer A. Goren ,  John McCoy

IPC分类号： A61K31/445 ,  A61K31/335 ,  A61K31/201 ,  A61K31/192 ,  A61K31/12 ,  A61K31/4427 ,  A61K31/4164 ,  A61K31/4152 ,  A61K31/16 ,  A61K38/03 ,  A61P11/00 ,  A61P31/14 ,  A61K31/05 ,  A61K31/4166 ,  A61K31/473 ,  A61K31/4439 ,  A61K31/57 ,  C07K16/28 ,  A61K31/4709 ,  A61K31/277 ,  A61K31/437 ,  A61K38/09 ,  C12N15/113 ,  A61K33/18 ,  A61K31/4155 ,  A61K31/58 ,  A61K31/337 ,  C07K14/71 ,  A61K31/167

摘要： The present disclosure includes methods, systems, kits and compositions for treating, preventing and diagnosing viral infections, specifically SARS-CoV-2 infections, with an anti-androgen and anti-thyroid medication, a thyroid receptor antagonist, a TGF-β inhibitor or a combination thereof. The present disclosure also describes methods and compositions for the treatment of viral respiratory diseases, specifically SARS-CoV-2 infections, including anti-androgens, anti-thyroid medications, thyroid receptor antagonists, TGF-β inhibitors, RXR inhibitors, furin inhibitors or other agents to disrupt the androgen signaling.

公开(公告)号：US20210121443A1

公开(公告)日：2021-04-29

申请号：US16714867

申请日：2019-12-16

申请人： NATIONAL TAIWAN UNIVERSITY

发明人： Ying-Lien Chen ,  Hao-Tai Ko ,  Li-Hang Hsu ,  Sheng-Yung Yang

IPC分类号： A61K31/4152 ,  A61K31/436 ,  A61P31/10

摘要： Provided is a method of inhibiting the growth of a fungus using eltrombopag, wherein the fungus is selected from the group consisting of Cryptococcus, Candida glabrata, and Trichophyton rubrum. Also provided are a combination agent that includes eltrombopag and a macrolide calcineurin inhibitor and a method of using the combination agent for inhibiting the growth of Cryptococcus. Also provided is a method of inhibiting virulence factor formation in Cryptococcus using eltrombopag.